Latest for Vivace Therapeutics


A milestone in targeted oncology and looking ahead

In honor of this historic event, we want to share a few thoughts about the future of targeted oncology and where we are making investments at Canaan.

Endpoints News: Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year

With $30 million in Series C financing, Vivace is aiming to test one of its candidates against that pathway starting in early 2021.